OGT, CCMC announce license agreement
OXFORD, United Kingdom—Oxford Gene Technology and the Cancer Cytogenomics Microarray Consortium (CCMC) have signed a license agreement for the creation of a whole-genome, cancer-specific microarray, which includes probes for more than 500 cancer genes and 130 cancer-associated genomic regions from the CCMC's design for hematological and solid tumors. The goal is an improvement in cancer research by enabling accurate identification of DNA copy number changes.
"The CCMC license agreement is an endorsement of both OGT's expertise in gene-focused arrays and our commitment to developing accurate solutions for early cancer detection and accurate disease characterization," Dr. Mike Evans, CEO at OGT, said in a press release. "We are proud to be able to contribute to the good work undertaken by the CCMC to further cancer research through increasing access to more comprehensive, accurately interpreted molecular information."